Note 10. Share-based Compensation:

During the six months ended December 31, 2019 and 2018, the Company granted 0.7 million and 0.9 million stock options at weighted average grant prices of $190.73 and $174.10 and weighted average fair values of $37.00 and $34.69, respectively. During the six months ended December 31, 2019 and 2018, the Company granted 30,858  and 53,903 restricted stock units at a weighted average fair value of $192.08 and $170.74, respectively. During the six months ended December 31, 2019 and 2018, the Company granted 15,398 and 14,887 shares of restricted common stock shares at a weighted average fair value of $193.48 and $125.05.

Stock options for 287,595 and 189,627 shares of common stock with total intrinsic values of $35.3 million and $16.3 million were exercised during the six months ended December 31, 2019 and 2018, respectively.

Stock-based compensation expense of $10.1. million and $6.9 million was included in selling, general and administrative expenses for the quarter ended December 31, 2019 and 2018, respectively. Stock-based compensation expense of $18.5 million and $18.4 million was included in selling, general, and administrative expenses for the six months ended December 31, 2019 and 2018, respectively. Additionally, the company recognized $0.5 million and $0.9 million in cost of goods sold in the quarter and six months ended December 31, 2019 respectively. As of December 31, 2019, there was $38.2 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock. The weighted average period over which the compensation cost is expected to be recognized is 2.1 years.